AGER and prostate carcinoma: After adjustment for the effects of age at diagnosis, PSA levels at diagnosis, clinical T stage, pathologic T stage, pathologic N stage, pathologic Gleason grade group, perineural invasion, seminal vesicle invasion, lymphovascular invasion, biochemical recurrence and D’Amico classification, a significant difference (p = 0.019) and adjusted odds ratios (AORs) = 0.628 with CIs = 0.426–0.926 was observed in prostate cancer patients with or without grade group upgrade with RAGE rs2070600 ‘GA’ genotype compared with the wild‐type (WT) ‘GG’ carriers (Table 2).